---
title: "IN8bio, Inc. (INAB.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/INAB.US.md"
symbol: "INAB.US"
name: "IN8bio, Inc."
industry: "Biotechnology"
datetime: "2026-06-13T22:35:40.425Z"
locales:
  - [en](https://longbridge.com/en/quote/INAB.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/INAB.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/INAB.US.md)
---

# IN8bio, Inc. (INAB.US)

## Company Overview

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company also develops INB-619, a gamma-delta TCE targeting CD19 for both oncology and autoimmune diseases; INB-300, a nsCAR-enabled DeltEx product candidates targeting difficult liquid tumors and extracranial solid tumors; INB-500, an induced pluripotent stem cell derived gamma-delta T cells that are in preclinical phase for treatment of cancer; and INB-600, a gamma-Delta T cell engager. In addition, it is developing INB-619, a gamma-delta TCE targeting CD19 for potential applications in both oncology and autoimmune diseases.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [in8bio.com](https://in8bio.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.74 | 162 | - | - | - |
| PB | 0.62 | 54 | 0.78 | 0.63 | 0.54 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-06-04T04:00:00.000Z

Total Analysts: **4**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 3 | 75% |
| Overweight | 1 | 25% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 1.43 |
| Highest Target | 10.00 |
| Lowest Target | 4.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/INAB.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/INAB.US/norm.md)
- [Related News](https://longbridge.com/en/quote/INAB.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/INAB.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**